Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CDC25B | P30305 | 2/20 | 0.36 |
| ▸ | TDP2 | O95551 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | APAF1 | O14727 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3697487 | 0.76 | MEN1 (0.39) | MEN1KMT2ACDC25BTDP2MAOA | |
| SCHEMBL25297698 | 0.73 | IDO1 (0.33) | NPC1IDO1 | |
| SCHEMBL2072302 | 0.73 | CDC25B (0.39) | MEN1KMT2ACDC25BTDP2MAOA | |
| SCHEMBL3705255 | 0.72 | HSD11B1 (0.34) | MEN1KMT2ACDC25BTDP2MAOA | |
| SCHEMBL29714477 | 0.66 | MEN1 (0.50) | MEN1KMT2ACDC25BTDP2MAOA | |
| SCHEMBL112133 | 0.66 | MEN1 (0.50) | MEN1KMT2ACDC25BTDP2MAOA | |
| SCHEMBL19888 | 0.66 | MEN1 (0.50) | MEN1KMT2ACDC25BTDP2MAOA | |
| SCHEMBL9569910 | 0.66 | PTPN1 (0.40) | MAOAMAPK1TDP1MAOB | |
| SCHEMBL30218501 | 0.64 | MEN1 (0.47) | MEN1KMT2ACDC25BTDP2MAOA | |
| SCHEMBL879050 | 0.62 | CDC25B (0.39) | MEN1KMT2ACDC25BTDP2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-2776393-B1 | NAMPT INHIBITORS | ABBVIE INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9758511-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170253562-A1 | Nampt Inhibitors | ABBVIE INC (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170135994-A9 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170065575-A1 | NAMPT INHIBITORS | ABBVIE INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160193209-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160184282-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184281-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160168134-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20140336168-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2014-11-13 | — | — | US | disclosed |
| US-20140336167-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20130303511-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303509-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303510-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303508-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2640704-A1 | NAMPT INHIBITORS | Abbvie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067963-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122924-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122924-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | MEN1 1333/4885KMT2A 1248/4885CDC25B 2595/4885 |
| US-20160168134-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | MEN1 1139/4885KMT2A 2025/4885CDC25B 2577/4885 |
| US-20130303508-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20160184282-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20130303511-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20170253562-A1 | Nampt Inhibitors | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20170065575-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20140336168-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20160184281-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20140336167-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20130303510-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20170135994-A9 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20160193209-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
| US-20130303509-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MEN1 2691/4885KMT2A 2175/4885CDC25B 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.